ZBH

Business Context and Reporting Period

Company: Zimmer Holdings, Inc. (Note: Filing reflects pre-spin-off entity; current name is Zimmer Biomet Holdings, Inc.)
Reporting Period: Three months ended March 31, 2009 (Q1 2009)
Business Overview: Global leader in orthopaedic reconstructive implants, dental implants, spinal implants, trauma products, and related surgical products. Operations span three geographic segments: Americas, Europe, and Asia Pacific.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 6% year-over-year. This was driven by a 5% negative impact from foreign exchange rates (stronger U.S. Dollar), a 1% decline in volume/mix, and flat pricing.
• Profitability: Operating profit fell 16% to $279.8 million, and net earnings dropped 16% to $202.2 million. Despite the revenue decline, gross margin improved slightly to 76.8% due to foreign currency hedge gains recognized in cost of products sold.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose to $423.7 million (42.7% of sales) from $417.8 million (39.4% of sales), driven by litigation costs, compliance initiatives, and the Abbott Spine acquisition. R&D expenses increased to $51.8 million.
• Debt and Liquidity: Long-term debt increased by $200.3 million to $660.4 million, primarily to fund share repurchases and the Abbott Spine acquisition. Cash from operations decreased by $58.1 million.
• Share Repurchases: The company repurchased 8.6 million shares for $301.4 million during the quarter.

Guidance, Outlook, and Risks

• Outlook: Management expects global selling prices to remain flat to slightly negative in 2009 due to healthcare cost containment. A stronger U.S. Dollar is estimated to negatively impact full-year sales by approximately 4%. Sales growth is expected to be slower than the market in the near term due to disruptive factors.
• Disruptive Events: The company estimates cumulative market share losses of 1.5% in knees and 2.0% in hips due to the 2008 suspension of the Durom Cup marketing, voluntary recalls of OSP products, and compliance initiatives. Additional share losses of 0.1% (knees) and 0.2% (hips) occurred in Q1 2009.
• Legal and Regulatory Risks:
  • Durom Cup Litigation: A provision of $56.1 million remains for product liability claims. Management believes the likelihood of material additional valid claims is not probable, though new claims are being reviewed.
  • Government Investigations: The Deferred Prosecution Agreement (DPA) with the U.S. Department of Justice expired in March 2009, and the criminal complaint was dismissed. However, the company remains subject to a Corporate Integrity Agreement (CIA) through 2012. Non-compliance could result in exclusion from federal healthcare programs.
  • SEC Investigation: An informal investigation regarding potential Foreign Corrupt Practices Act violations is ongoing.
• Unusual Items: Inventory levels increased, resulting in 373 days of inventory on hand (up 29 days from year-end 2008), attributed to planned field deployments and reduced manufacturing volumes to match lost market share.

Investor Verification Checklist

• Durom Cup Liability: Verify the sufficiency of the $56.1 million provision against the volume of new claims received subsequent to March 31, 2009.
• Market Share Recovery: Monitor quarterly data to confirm if the estimated market share losses in knee and hip segments have stabilized as projected.
• Regulatory Compliance: Track adherence to the Corporate Integrity Agreement (CIA) terms to avoid exclusion from Medicare/Medicaid.
• Currency Hedging: Assess the sustainability of gross margin improvements driven by foreign currency hedge gains versus the underlying operational revenue decline.
• Inventory Turnover: Watch for potential obsolescence charges given the significant increase in days of inventory on hand (373 days).